Progenity, Inc. (PROG)
| Market Cap | 298.91M |
| Revenue (ttm) | 80.51M |
| Net Income (ttm) | -167.48M |
| Shares Out | 46.63M |
| EPS (ttm) | -3.59 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $5.47 |
| Previous Close | $5.57 |
| Change ($) | -0.10 |
| Change (%) | -1.80% |
| Day's Open | 5.41 |
| Day's Range | 5.40 - 5.61 |
| Day's Volume | 319,879 |
| 52-Week Range | 3.08 - 15.92 |
SAN DIEGO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing...
New York, New York--(Newsfile Corp. - February 22, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc. (NASDAQ: PROG) ("Silk Road" or the "Company"). Such i...
NEW YORK, Feb. 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc. ("Silk Road" or the "Company") (NASDAQ: PROG). Such investors are advise...
SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testin...
Progenity applauds focus on preeclampsia biomarkers as it prepares for the launch of the Preecludia™ test Progenity applauds focus on preeclampsia biomarkers as it prepares for the launch of t...
New York, New York--(Newsfile Corp. - February 11, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc. ("Silk Road" or the "Company") (NASDAQ: PROG). Such i...
SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular tes...
Progenity's (NASDAQ:PROG) stock has been falling Monday, down 6.19% to a price of $5.9. Monday the stock has been traded at a volume of 209.31 thousand, about 29.44% of its recent 30-day volum...
The company celebrates its ten-year anniversary and looks toward future innovations The company celebrates its ten-year anniversary and looks toward future innovations
Total 2021 revenue expected to grow by up to 30% 1 , reaching a range of $130 to $145 million
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular tes...
Initial public offerings (IPOs) have been a hot topic of late, with big names like Airbnb and DoorDash having some of the biggest showings this year.
SAN DIEGO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular tes...
Adam Johnson of BullseyeBrief.com presented Tuesday at the Benzinga Global Small Cap Conference, discussing his fund of small-cap stock picks on Bullseye Brief, where subscribers can track his...
SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular tes...
SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing...
SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG) today announced the pricing of its offering of $75.0 million aggregate principal amount of 7.25% convertible senior ...
SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing...
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG) today announced its intention to offer, subject to market and other conditions, $75 million aggregate principal amou...
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing...
High sensitivity and high negative predictive value (NPV) observed for ruling out the risk of preeclampsia High sensitivity and high negative predictive value (NPV) observed for ruling out the...
SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular tes...
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular tes...
SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular tes...
Progenity, Inc. (PROG) CEO Harry Stylli on Q3 2020 Results - Earnings Call Transcript
SAN DIEGO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular tes...
SAN DIEGO, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular tes...
Announces Expansion of its COVID-19 Testing Offering
Los Angeles, California--(Newsfile Corp. - October 27, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Progen...
New York, New York--(Newsfile Corp. - October 27, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Progenity, Inc. (NASDAQ: PROG) pursuant and...
Oral and poster presentations feature data on the use of PIL Dx to assess and diagnose SIBO Oral and poster presentations feature data on the use of PIL Dx to assess and diagnose SIBO
New York, New York--(Newsfile Corp. - October 26, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Progenity, Inc. ("Progenity" ...
Los Angeles, California--(Newsfile Corp. - October 26, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Progen...
New York, New York--(Newsfile Corp. - October 26, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Progenity, Inc. (NASDAQ: PROG) pursuant and...
LOS ANGELES--(BUSINESS WIRE)---- $PROG #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming October 27, 2020 deadline to file a lead plaintiff motion in the class a...
NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Progenity, Inc. ("Progenity" or "the Company") (NASDAQ: PROG...
Los Angeles, California--(Newsfile Corp. - October 23, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Progen...
New York, New York--(Newsfile Corp. - October 22, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Progenity, Inc. (NASDAQ: PROG) pursuant and...
[DATELINE] The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Progenity, Inc. (NASDAQ: PROG) ("Progenity" or "the Compan...
Los Angeles, California--(Newsfile Corp. - October 21, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Progen...
New York, New York--(Newsfile Corp. - October 19, 2020) - Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating claims against Prog...
NEW YORK, Oct. 17, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Progenity, Inc. ("Progenity" or the "Company") (NASDAQ: PROG). Such investors are advise...
New York, New York--(Newsfile Corp. - October 15, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Progenity, Inc. (NASDAQ: PROG) pursuant an...
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Progenity, Inc. (NASDAQ: PROG) pursuant and/or traceable to the Company’s ...
SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular tes...
New York, New York--(Newsfile Corp. - October 7, 2020) - Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating claims against Proge...
NEW YORK, Oct. 5, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Progenity, Inc. (NASDAQ: PROG) pursuant and/or traceable to th...
NEW YORK and SAN DIEGO, Oct. 5, 2020 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein") announces that a federal securities class action lawsuit has been filed agai...
New York, New York--(Newsfile Corp. - October 5, 2020) - Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating claims against Progen...
New York, New York--(Newsfile Corp. - October 2, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Progenity, Inc. (NASDAQ: PROG) pursuant and/...
About PROG
Progenity, a biotechnology company, provides complex molecular and specialized testing services to physicians, clinicians, and their patients in the United States. It offers testing services for common hereditary disorders, cystic fibrosis, spinal muscular atrophy, fragile X syndrome, and Jewish genetic diseases; pan-ethnic carrier screening services; non-invasive prenatal, miscarriage, and pharmacogenetic testing services; and ovarian assessment reports for women. The company also provides pediatric testing services. Progenity, Inc. was former... [Read more...]
| Industry Biotechnology | IPO Date Jun 19, 2020 |
| CEO Harry Stylli | Employees 702 |
| Stock Exchange NASDAQ | Ticker Symbol PROG |
Financial Performance
In 2019, Progenity's revenue was $143.99 million, an increase of 12.51% compared to the previous year's $127.97 million. Losses were -$148.04 million, 14.7% more than in 2018.
Analyst Forecasts
According to 5 analysts, the average rating for Progenity stock is "Strong Buy." The 12-month stock price forecast is 9.40, which is an increase of 71.85% from the latest price.